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Background: The pluranrycins are a class of antitumor 
antibiotrcs that exert their biological acttvrty through 
interaction vvith DNA. Recent studies with the analog 
altromycin B have determined that there agents interca- 
late into the DNA nrolecule, position carbohydrate sub- 
Ttituwts into both major and minor grooves, and alkylate 
the L?NA nlolecule by epoxide-mediated electrophilic 
attack on N7 of guanine located to the 3’ side of the 
drug molecule. Alkylation is sequence dependent and 
appears to be modulated by glycoside substituents 
attached ‘rt the corners of a planar chromophore. The 
altromycin B-like analogs preferentially alkylate 5’AG 
sequences; hedamycin-like analogs prefer 5’TG and S’CG 
sequences. Althongh the mechanism of guanine nrodifi- 
cation by Jtromycin B has been extensively studied, the 
nrech~tnicm of action of hedamycin has not been 
previously determined. 
Results: Using high-field NMR, we have shown that 
hedamycin stacks to the 5’ side of the guanine nucleotide 
at the site of intercalation in a LINA decamer, positioning 
both anrinosaccharides into the minor groove to direct 
alkylation by the eposide nloiety on N7 of guanine.The 
Cl 0 linked N,N-dimethylvancosatnine sugar moiety 
interacts to the 5’ side of the intercalation site. while the 
C8 linked anglosatnine moiety interacts to the 3’ side.The 
binding interactions of the two aminosugars steer the C2. 
double eposide located in the major groove into the 
proximity of N7 of guanine. Unexpectedly, it is not the 
first epoxide that undergoes electrophilic addition to N7 
of guanine, which would correspond to altromycin B. but 
the second, terminal epoxide. 
Conclusions: We have used two-dimensional NMR to 
elucidate the sequence-selective recognition of DNA by 
hedanrycin and the mechanism of covalent modification 
of guanine by this antibiotic. Characterization of the 
intermolecular interactions between both hedamycin and 
altromycin B and their targeted DNA sequences has 
yielded a better understanding of the reasons for varia- 
tions in sequence selectivity and alkylation reactivity 
anrong the plurannycin compounds. 
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Introduction 
Hedamycin and altromycin B are two of the most biologi- 
cally potent and structurally complex natural products of 
the pluramycin family of autitumor antibiotics (Fig. 1). 
Extensive studies of the pluramycin analog, altromycin B, 
have clearly shown that this family of antibiotics achieves 
actrvrty by intercalating and alkylating the 1INA molecule 
[ 1.21. Structurally, hedamycin and altromycin B represent 
two distinct subgroups within the pluramycin family, 
namely the classical pluramycins and the altromycins. 
Although bearing identical JH-anthra[ 1,2-b]pyran- 
1,7,1 Ztrione chromophores, the subgroups differ struc- 
turally in the attached substituents at the C3, C5, C8, and 
Cl 0 positions [3-l 21 .These differences translate into vari- 
ations in biochemical activity, that is, alkylation reactivity 
and sequence selecttvtty [ 131. Both subgroups require a C2 
epoxide functionality for high cytotoxic activity as well as 
for IINA alkylation through N7 of guanine [5].The clasci- 
cal pluramycins, represented by hedamycin, bear two 
aminosugars. an anglosamine attached to the CX position 
and an N,N-dimethylvancosamine attached to the C 10 
position.Various substituents can be found at the C2 posi- 
tion among members of this subgroup, including a vinyl 
substituent (kidamycin) [14-l 61, a vinylepoxide (plura- 
mycin A) [ 17,181, a single epoxide (epoxykidamycin) [19], 
or a double epoxide (hedamycin) [X-22]. The 
altromycins, on the other hand, bear an aminodisaccharide 
on the C IO position, an invariant single epoxide at the C2 
position, and in nrany cases (altromycin B), a methyl ester- 
linked 6-deoxy-3-O-methylaltrose attached through the 
CS position 133%251. 
Recent investigations into the interaction between 
altromycin B and l)NA have revealed a general mode of 
DNA interaction for the pluramycins as a group and have 
indicated possible roles for the C5, C8 and Cl0 linked 
glycosidic functionalities in 1INA sequence recognition 
[ 1,2]. These recent studies clearly demonstrate that 
altromycin B threads the DNA molecule, intercalates to 
the 5’ side of the modified guanine. and positions a 
neutral altrose moiety in the major groove and an 
aminodisaccharide in the minor groove.Thus positioned, 
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altromycin B alkylates DNA through N7 of guanine in 
the major groove by electrophilic attack by the epoxide 
attached to the C2 position of the tetracyclic chro- 
mophore. To decipher the functional significance of the 
different structural motifs displayed by the classical 
pluramycins and the altromycins, namely the C2, C5, 
C8 and Cl0 substituents, the contrasting pluramycin 
analog, hedamycin, has been reacted with the 
[d(GATG*TACATC)], (* denotes site of covalent modi- 
fication and underlined is the site of intercalation) duplex 
to form a bis-adduct (Fig. 2). Resolving the molecular 
interactions that hedamycin makes with DNA provides a 
basis for understanding hedamycinh demonstrated 
5’(Py)G* (Py = pyrimidine) alkylation selectivity [13], the 
functional importance of the second, terminal epoxide, 
and the increased alkylation reactivity demonstrated by 
hedamycin over the altromycins. 
Although hedamycin alkylates N7 of guanine in a 
fashion similar to altromycin B, it does so through Cl 8 
of the terminal epoxide as opposed to the equivalent 
site (C16) through which altromycin I3 alkylates 
guanine. Like altromycin B, hedamycin also intercalates 
the DNA molecule and stacks to the .5’ side of the 
modified guanine, thereby positioning both the CX and 
Cl0 aminosaccharides for interaction in the minor 
groove. Hedamycin achieves its 5’(Py)G* sequence 
selectivity through interactions between the two 
aminosugars and the 02 carbonyl of pyrimldmes 
located in the minor groove. 
Results 
Due to the serious stability limitations of guanine N7-alkyl 
adducts 12,261 (C. Lin & D.J. Patel, personal communica- 
tion), a noncovalent classical pluramycin analog was first 
chosen for NMR studies. The [d(GATGTACATC)l, 
decamer duplex was mltlally reacted with the noncovalent 
analog kidamycin. As the ligand was titrated into the DNA 
duplex sample, analysis of one-dimensional NMR spectra 
revealed general broadening of the proton spectrum, 
Fig. 1. Structures of representative 
pluramycin antibiotics. The family sub- 
divides by structure into two distinct 
groups: the classical pluramycins 
(depicted by kidamycin, epoxy- 
kidamycin, pluramycin A, and 
hedamycin) and the newly discovered 
altromycins (depicted by altromycins 6 
and HI. Sapurimycin represents the 
simplest pluramycin analog. 
indicative of non-specific interaction with the DNA mole- 
cule. Subsequently, an identical DNA sample was reacted 
with two equivalents of the analog hedamycin, in which 
the C2 vinyl functionality of kidamycin is replaced with a 
reactive double epoxide.The addition of 2: 1 molar equiva- 
lents of hedamycin to the IO base-pair DNA duplex 
yielded a C2 symmetric diadduct that exhibited nine 
methyl resonances. Samples proved to be marginally more 
stable than the previously studied altromycin B diadducts, 
but degraded similarly into a complex mixture of products 
over the span of four to five days. Samples also displayed a 
high degree of aggregation and had to be diluted to dimin- 
ish line broadening at the expense of signal intensity. For 
similar reasons, acquisition of data was carried out at 30 ‘C, 
which also minimized problems with aggregation. 
H3' 
, /k/H9 
H3" 
N,N-Dimethylvancosamine 
Fig. 2. The structures and numbering schemes of hedamycin and 
the DNA decamer used in this study. Shown are sites of 
intercalation between 3T and 4G and covalent modification (4G). 
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Assignment of the hedamycin proton resonances 
Thr hedamycin proton resonances (Table 1) are divided 
into four regions of the hedamycin molecule: the aro- 
111,1t1c cl1rolllophol-e. the CX linked anglwanine, the 
C 10 linked N,N-dirn~thylvn~~~~~s~~~lli~~~ and the C2 
double cpoxide. Protons in each region mwt’ assigned 
u\illg tot,d correlation spectroscopy (TOCSY). double 
qu,ll~tunl tiltered correlation spectroscopy (I)QF- 
COSY) dnd nuclear Overhduwr effect spectroscopy 
(NOESY) NMI< taxperinlent~ [27-301. In the first 
group> of resonmccs, those attached directly to the 
intercalating chroumphore. the HC) resonance was iden- 
tified by NOESY connectivitiec to the HZ’, 3’ m&y1 
md 4” methyl locdtcd on the aminosugars attached to 
the CX md (:I() positions. The 5 methyl (singlet) 2nd 
the adjacent HO proton were assigned bdsed on a 
NOESY connectivity to each other and n wr,tk contact 
betmmm the 5 ulrthyl md H3 resonances. The H3 
proton rt’son~lnce 1~~1s easily assigned based on NOESY 
connectivities to resonances mocinted with the C3 
rposid~ a-iii. 
In the CX linked anglosamine (designated in single- 
prinlc numbers), the proton resonances mutually coupled 
a-ound the sugar ring in the LIQF-COSY. Couplings 
bet\wcn HO’ and HS’a, HO’ and Hj’b, H5’b and H4’, H-I’ 
,uld H3’. and H3’ and H2’ establish these proton assign- 
ment\. The 2’ m&y1 resonance (doublet) was easily 
Table 1. Comparison oi the hedamycin chemical shifts in the 
bis-hedamycin-[d(CATGTACATC)]I diadduct and the free drug. 
Chemical shifts (ppm) of hedamycin 
1 H assignment” in the bis-adductb free drugC 
H3 6.16 6.46 
H6 6.36 8.00 
5CH, 2.33 2.99 
H9 8.22 8.33 
15CH, 1.08 1 .96 
til6 3.34 3.32 
Hl 7 3.78 2.89 
HI 8 5.09 3.11 
19CH, 1.73 1.44 
H2’ 3.94 3.55 
J’CH 1 1.57 1.43 
H3’ 3.38 3.19 
4’N(CH i)2 2.73 2.32 
H4’ 3.50 2.93 
HS’a 1.05 1.20 
H5’h 1.80 2.50 
t-16’ 5.39 5.45 
H2” 4.32 4.04 
L”CH I 1.48 1.51 
H.3” 3.78 3.35 
4”CH 
I”N(?H 
1 .16 0.71 
i)L 2.90 2.22 
HS”1 ‘ 2.58 2.10 
H5”b 3.00 2.70 
Hh” 5.57 5.45 
C’For numbering, see Figure 2. 
‘Xhemic-al shifts referenced to H,O in 99.9 % D,O. 
Xhemical shifts in chloroform [5,221. 
identified through coupling to the H?.The 4’ dimethyl- 
amino signal ~~3s identified by resonance intensity, chen- 
ical shift, md NOESY connrctivities to the other 
protons on this sugar. The HS’,l and HS’b ~I‘SO~JIIC‘CS 
krerr distinguished bawd on stronger NOE connectivi- 
ties bet\veen the H5’b to the HO’ and H1’ protons th,ln 
the equivalent NOE\ for the HJ’,l rt‘sonmcC. 
In the Cl 0 linked N,N-di~nrth~lvan~~)~~~~li~l~ moiet) 
(designated with double-prime numbers), the 4” 
diiii~thyl31iiino signal is e.lsily identified by chemical 
shift. onr-dimensional intensity. and strong NOESY 
contact to the 4” methyl rcsonmce (singlet). H5”,1 and 
H5”b protons both showed NOESY contacts to the 4” 
methyl md 1” di~~~rthylanlino signals. Additionally, the 
HJ”a proton couples \vith both the H5”b md the HO” 
protom.The 3” methyl (doublet) coupled to the H3” md 
showed NOE cont‘~cts to both 4” substituents.The H3” 
proton IV;IS assigned based on NOESY connectlvltlrs to 
both the 4” md 2” methyl dud proton resonances. The 
proton assignments of HJ”b and IHS”a mwe distinguishrd 
based on correlation of their chemical shift5 to that of 
the ti-ee drug and a stronger NOE connectivity between 
the 4” methyl to the H5”b than between the 4” methyl 
to the H5”a resonmcc. 
Proton resonances in the last group associattd \vith the 
site of covalent attnchment of the drug to the IINA mw-e 
wigned through mutml couplings between vicinJ 
protons on the C2 epoxide arm (Fig. 3). The H16 
coupled in the LQF-COSY to the HI7 rt‘sonanct‘. 
Lvhich ill turn coupled to the HI X proton.The H 1 X Gmi- 
larly coupled to thr terminal 19 methyl (doublet).The 15 
methyl (singlet) mw assigned by NOESY contacts to the 
H3, H16, HI 7 and H18 protons. Carbon-l 3 chemical 
shifts for the backbone of the C2 eporide mn werr ida- 
tified through single-bond and multiple-bond ‘H-‘%I 
correlXions to the previously identified proton reso- 
nances. The CIS. C16, C17, Cl8 md <IlO resonances 
were all assigned through couplin g to their respecti\re 
attached proton rewnance, xid the Cl 1 rtwndnce ~35 
,Issignrd b,wd 011 long-range coupling to the Ii lwthyl. 
Assignments of DNA proton resonances 
DNA proton assignments of the IO base-pair duplex and 
its bis-hedamycin diadduct (Table 2) were achieved 
through established methods 1311 using TOCSY, NOESY 
and DQF-COSY experiments to create \I-alk\ leading 
fi-on1 the 5’ end to the 3’ tmd of the DNA molecule (Fig. 
4). To identi% protons overlapping the water resonance, 
namely the STH3’ and the 4CH3’ resonances, a 1 SO ms 
NOESY experiment WJS collected ‘it 10 “C, mhich shifted 
these resonmces slightly downfield of the water resonance. 
The aronmic to ,wonmtic, aromatic to HI’, aromatic to 
HZ’/?“, and aromatic to H3’ resonances all dmmnstrate 
breaks in the walks at the 3T-4G and 7C-8T steps due to 
insertion of the intercalating chromophore at this position 
on the DNA molecule. Interestingly, the STH 1’ resonance 
is upfield shifted from 5.71 ppm to 5.17 ppln upon 
hedainycill-duplex adduct formation, presumably due to 
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0 
Fig. 3. Assignments for the proton resonances associated with the reacted C2 double-epoxide substituent. A DQF-COSY experiment is 
shown left of the diagonal with a corresponding chemical structure in which couplings between HI 8 and I9 methyl (A), HI 8 and H17 
(B), and H16 and H17 (C) are identified. A NOESY experiment (150 ms mixing time) is shown right of the diagonal with a correspond- 
ing chemical structure showing cross-peaks between H18 and H16 (D), H17 and 19 methyl (E), H16 and 19 methyl (F), H17 and 15 
methyl (G), H16 and 15 methyl (H), and 19 methyl and 15 methyl (I). 
its proximity to the aromatic system of the drug, which 
extends into the minor groove. 
Cl8 of hedamycin alkylates N7 of guanine via an 
S,2 mechanism 
Both the base and the site of covalent attachment to the 
DNA molecule are identified by the chemical nature of 
the 4GH8 aromatic proton.This proton, which was identi- 
fied and characterized in 95 o/o H20, has become extremely 
labile and now resonates at 9.6 ppm, which is -2 ppm 
downfield of the equivalent proton resonance in the 
unmodified 30 base-pair duplex (7.77 ppm). The unu- 
sually acidic nature of this H8 aromatic proton is a direct 
result of alkylation that occurs through N7 of guanine, 
thereby forming a cationic drug-guanine lesion. These 
results are consistent with other reported N7 alkyl-guanine 
adducts, specifically aflatoxin, sapurimycin and altromycin 
B [2,26] (C. Lin & D.J. Patel, personal communication). 
In comparison to the unreacted C2 double epoxide 
functionality of hedamycin, the H18 and Cl8 demon- 
strate the greatest change in chemical shift upon DNA 
adduct formation, -2 and 20 ppm downfield, respec- 
tively, whereas H17 and Cl7 demonstrate only marginal 
downfield shifts of -1 and 14 ppm, respectively (Fig. 5, 
Table 3). The resonances associated with the C14-Cl6 
epoxide demonstrate only small chemical shift differ- 
ences over the free drug. It is therefore proposed, based 
Table 2. Comparison of the DNA proton chemical shift+ of the bis-hedamycin-[d(GATG*TACATC)lj duplex diadduct with the 
unmodified duplex. 
Base HB/H6 HS/SCH, H2 HI' H2’ H2” H3’ H4’ 
1G 7.85 (0.00) 
2A 8.20 (-0.13) 
3T 7.30 (+0.15) 
4G* 9.60 (+l .80jb 
5T 7.10 (-0.10) 
6A 8.20 (-0.03) 
7c 7.34 (+0.14) 
8A 8.62 (+0.42) 
9T 7.10 (-0.12) 
1oc 7.45 (-0.15) 
- - 
1.12<-0.30) 7.88 - (-0.07) 
- 
1.13 (-0.24) - 
- 7.50 (+0.08) 
5.20 (-0.10) - 
- 6.88 (-0.25) 
1 .27 (-0.17) - 
5.52 (-0.18) - 
5.58 (-0.07) 2.52 (-0.04) 2.70 (-0.05) 4.83 (-0.02) 4.12 (-0.07) 
6.18 (-0.13) 2.60 (-0.15) 2.85 (-0.13) 5.03 (0.00) 4.40 (-0.07) 
6.10 (+0.31) 2.25 (+0.13) 2.38 (-0.09) 5.00 (+0.14) 4.42 (-0.29) 
5.82 (-0.11) 2.32 (-0.25) 2.47 (-0.28) 4.75 (-0.18) 4.45 (+0.07) 
5.18 (-0.52) 2.15 (+0.07) 2.15 (-0.31) 4.75 (-0.12) 3.87 (-0.43) 
6.11 (-0.07) 2.60 (-0.06) 2.82 (+O.Ol) 4.92 (-0.09) 4.40 (0.00) 
5.68 (-0.34) 2.20 (+0.15) 2.34 (-0.03) 5.04 (+0.24) 4.24 (0.00) 
6.40 (-0.19) 2.81 (+0.19) 3.05 (+0.17) 5.13 (+0.18) 4.20 (-0.18) 
5.86 (-0.17) 2.03 (-0.02) 2.36 (-0.10) 4.88 (+0.04) 4.14 (-0.24) 
6.18 (-0.17) 2.25 (0.00) 2.25 (0.00) 4.52 (-0.03) 4.19 (-0.21) 
aReferenced to H,O in 99.9 % D,O unless otherwise noted. Chemical shift differences: (-) and (+) represent upfield and downfield 
shifts, respectively. Shown in bold are those greater than 0.2 ppm. 
bExchangeable proton observed in 95 % H,O. 
*Site of covalent modification by hedamycin. 
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Fig. 4. NOESY data (150 ms) showing 
the aromatic to HI ’ (left) and aromatic 
to H3’ walks (right). The intra-residue 
connectivities are identified with a base 
and number designation. Breaks in the 
walks due to ligand intercalation are 
indicated with arrows. Also shown are 
cytoslne H5 connectivities to their own 
Hh proton and the 5’ neighbor’s aro- 
matic proton. For 7C and 1 OC, these are 
shown by a single, broken vertical line. 
Note that cross-peaks associated with 
4CH8 are absent due to the rapid 
exe hange of this proton with D,O. 
- 
8.5 
6.0 5.5 5.0 
wm 
on chemical shifts and chemical shift changes, that N7 of 
guanine performs nucleophilic attack on C 18, leading to 
opening of the epoxide to form a hydroxyl on Cl7 (Fig. 
6). Medium to strong NOES between 1GH8 and both 
hedamycin H18 and H17, and only a medium to weak 
NOE between 4GH8 and hedamycin HI 6, also strongly 
argue for alkylation at C18. The relatively undisturbed 
chemical shifts of Cl3 and Cl6 suggest that the first, 
proximal epoxide associated with these two carbon 
atoms is chemically unmodified in the DNA adduct. 
Alkylation of the duplex oligomer yields only one set of 
proton resonances corresponding to a single species of 
adduct. This suggests that nucleophilic addition occurs 
through an S,J mechanism, inverting the stereo- 
configuration of the Cl8 chiral center. The stereo- 
chemistry reported in the crystal structure of hedamycin 
(14R, 16’S, 17R, 1%) [20] would then be converted to 
1 -CR, 16S, 17R, 1 XR by an S,2 nucleophilic addition to 
N7 of guanine. This stereo&emical configuration (see methyl of the DNA 
The C2 substituent is located in the major-groove side 
of the DNA helix and is positioned next to the co- 
valently modified strand, making NOESY contacts to 
both sides of the intercalation site (Fig. 7), confirming 
the site of intercalation. On the 5’ side of the intercala- 
tion site, the 3T methyl shows NOE contacts to 
hedamycin HI 6; 3TH6, 3TH2’, and 3TH2” show NOE 
contacts with hedamycin’s 15 methyl. On the 3’ side of 
the intercalation site, the 4GH8 and the 5T methyl show 
NOE contacts to the 19 methyl and HZ 8 of hedamycin. 
Also in this region of the duplex is the H3 resonance of 
hedamycin, which shows a medium cross-peak to the 3T 
Fig. 3) is supported by a strong NOE connectivity 
between hedamycin H18 and H16, a weaker NOE con- 
nectivity between Hlh and HI7 (medium), and strong 
NOES between 15 methyl and 19 methyl, 15 methyl and 
4GH8, and 19 methyl and 4GH8. 
Drug-DNA connectivities in the major groove 
0 
Fig. 5. Structure of the hedamycin C2 epoxide arm. Based on 
chemical shifs and chemical-shift differences (Table 3), it is Cl 8 
of the second epoxide that reacts with N7 of guanine. 
Table 3. ‘H and ’ 3C NMR chemical shifts (ppm) of the C2 side 
chain of hedamycin as the free drug and after reaction with 
the 10 base-pair duplex DNA”. 
1 H/13C Assignment ‘H 1% 
14 - t) 58.0 (+O.O) 
15 1.1 (0.0) 14.0 (-0.1) 
16 3.3 (0.0) 68.5 (+4.6) 
17 3.8 (+0.9)‘ 69.0 (+I 3.6) 
18 5.1 (+2.0) 78.7 (+23.3) 
19 1.7 (+0.3) 15.6 (-1.6) 
%hemical shift differences are reported in parenthesis: DNA 
adduct in D,O minus hedamycin in CDCI, [5,6,22] 
“Not applicable. 
CChemical shifts experiencing significant downfield shifts 
upon reaction with DNA are designated in bold. 
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Adjacent to the noncovalently modified strand in the 
major groove is the 5 methyl of the drug, which also 
shows contacts to both sides of the intercalation site.The 
5 methyl shows medium connectivities to 7CHh and 
7CH5 and a very weak connectivity to 8AH8, all of 
which are located in the DNA major groove. Located 
between the grooves is the hedamycin H6 proton, which 
shows weak contact to the major groove proton 7CH6 
and both a strong and a weak connectivity to 7CHl’ and 
7CH3’, located in the minor groove. A diagrammatic 
summary of these intermolecular connectivities in the 
major groove is shown in Figure 7. 
Drug-DNA connectivities in the minor groove 
Both the C8 linked anglosamine and the Cl0 linked 
N,N-dimethylvancosamine are located in the minor 
groove of the DNA molecule (Fig. 8a). The NOE 
Major groove s ?A 
11 , 
;4 
Fig. 6. The proposed mechanism of 
covalent modification of DNA by 
hedamycin. N7 of guanine performs 
nucleophilic attack on the terminal 
epoxide, forming a cationic lesion on 
the DNA. Subsequent depurination of 
the modified guanine results in DNA 
strand breakage 111. 
connectivities between the methyl groups of- each 
sugar and DNA are shown in Figure 8b. The N,N- 
dimethylvancosamine is positioned in the minor 
groove, oriented to the 5’ side of the intercalation site 
and making extensive NOESY contact with 2A, 3T, 
8A and 9T. While showing only a weak contact to 
5TH4’, the H2” proton shows a very strong NOE 
contact to the H9 proton located on the hedamycin 
chromophore. Based on this contact, the N,N- 
dimethylvancosamine is rotated to an orientation 
below the drug chromophore in the 5’ direction.This 
orientation is further supported by NOE contacts 
between the drug’s H6” and 5TH4’, the 2” methyl and 
C)TH4’, and between the 4” methyl and 2AH2, 3THl’, 
9TH3’ and 9TH5’. Furthermore, the 4” dimethylamino 
group makes medium to strong contacts to 2AH2, 
2AHl’, 3THl’, 3TH4’ and 8AH2. In contrast, the C8 
linked anglosamine orients to the 3’ side of the modi- 
fied guanine, making NOE contact primarily with the 
ST. hA, 7C and 8A residues. The H2’ and H6’ show 
strong NOE contacts to 8AHl’, the 2’ methyl shows 
NOE contacts to 8AHl’, 9TH5’/5” and 9TH4’, and 
the 4’ dimethylamino shows strong NOE contacts to 
5TH l’, 6AH2, hAH4’, 7CHl’ and 7CH4’. 
NMR-driven molecular modeling 
In a 100 ps solvated molecular dynamics simulation 
using 54 inter-drug-DNA, 76 intra-drug, and 166 
intra-DNA constraints for the complete bis-adduct, a 
molecular model was generated that reflects the NMK 
results (Fig. 9). In this NMK-derived model of the bis- 
hedamycin diadduct, the conjugated chromophore 
stacks between the 3T*8A and the 4G*7C base pairs in 
roughly a perpendicular orientation to the hydrogen 
bonds formed by the flanking base pairs.To accommo- 
.i date this interaction, the DNA has grossly distorted, Fig. 7. Summary of key ‘H-NOESY connectivities (150 rnsj 
between hedamycin and the DNA major groove. The drug shows 
opening the base pairs to twice the normal distance to 
connectivities to both sides of the intercalation site, reaffirming allow insertion of the drug chromophore. As predicted 
positioning of the tetracyclic chromophore between 3T and 4G. from the relatively large upfield shift exhibited by 
A weaker connectivity is shown with a broken arrow. 5THl’, the influence of the C8 aminosugar pulls the 
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Fig. 8. Summary of key ’ H-NOESY connectivities (a) and NOESY data (150 ms) (b) between hedamycin’s CII and Cl 0 sugar moieties 
and the DNA minor groove. In (a), NOE connectivities are shown in solid arrows. The NOESY data in (b) shows NOE connectivities of 
some of the proton and methyl resonances located in the minor groove. 
Fig. 9. Ster 
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tetracyclic chromophore slightly into the minor groove 
directly under this proton. Despite placing both 
aminosaccharides into the minor groove, the chro- 
mophore remains able to easily span the double helix to 
covalently attach to N7 of 4G in the major groove. 
In the major groove, hedamycin makes the most signifi- 
cant interaction with the DNA molecule, forming a 
covalent bond through Cl8 and N7 of 4G. Having a 
four-carbon span, the C2 epoxide arm easily joins the 
chromophore to N7 of guanine without causing signi- 
ficant distortion of 4G or the surrounding DNA. 
Associated with the noncovalently modified strand is 
the hedamycin 5 methyl, which is pulled in toward the 
floor of the major groove to make van der Waals 
contact with the 7CH5 and H6 protons. 
Positioned in the minor groove (Fig. 10) are both 
the C8 linked anglosamine and the Cl0 linked 
N,N-dimethylvancosamine moieties. The Cl0 linked 
N,N-dimethylvancosamine is directed toward the 5’ side 
of the intercalation site to interact with the covalently 
modified strand, namely the 3T residue.To the 3’ side of 
the intercalation site, the anglosamine moiety interacts 
in the minor groove primarily with 7C on the nonco- 
valently modified strand. On the basis of NMR evi- 
dence (see Fig. 8), indicating proximity of the 
dimethylamino in both sugars to the negatively charged 
02 carbonyl of each respective pyrimidine, we propose 
that a key interaction occurs through the formation of a 
hydrogen bond to the carbonyl, either directly or medi- 
ated through a water molecule. Molecular dynamics cal- 
culations were performed with direct hydrogen bonding 
restraints and with hydrogen bonding restraints medi- 
ated by a bound water molecule. Both situations satisfied 
NMR-derived constraints; however, simulations using 
bound water molecules, similar to those reported in the 
crystal structure with daunomycin 1321, were used to 
derive the reported structure. 
Discussion 
Comparison to other pluramycin adducts 
Hedamycin interacts with the DNA molecule in a very 
similar fashion to that reported in previous structural 
studies involving altromycin B adducted to 
[d(GAAA*TACTTC)12 [2] and sapurimycin adducted to 
[d(AATfi*CTATT)], (C. Lin & D.J. Patel, personal 
communication). Like the other two pluramycins, 
hedamycin threads the DNA molecule, covalently 
attaches to N7 of guanine, and stacks to the 5’ side of the 
modified guanine. Like altromycin B, the Cl0 linked 
vancosamine moiety and the closely related CX linked 
anglosamine are both positioned in the minor groove. 
Subtle structural differences between altromycin B 
and hedamycin give rise to variations in DNA 
sequence selectivity and reactivity. Differences in car- 
bohydrate substitution at the C5, C8 and Cl0 posi- 
tions of an otherwise similar chromophore appear to 
modulate alkylation sequence selectivity. Classical 
pluramycins, characterized by C8 and Cl0 aminosugar 
substitutions, demonstrate S’(Py)G* selectivity, while 
the altromycins, characterized by a Cl0 aminodi- 
saccharide and a C5 neutral sugar substitution, 
demonstrate 5’AG* selectivity [ 131. Because both 
noncovalent analogs, neopluramycin and kidamycin, 
show only nonspecific DNase I footprinting patterns, 
and kidamycin shows only nonselective binding to the 
IO base-pair DNA duplex in this study, it is probable 
that sequence selectivity is achieved largely through 
the covalent alkylation step as opposed to the initial 
precovalent binding step [13]. 
Recognition of the minor groove by hedamycin’s glyco- 
sidic substituents affects the orientation of the intercalating 
chromophore and, consequently, the proximity of the 
reactive C2 linked double epoxide to N7 of guanine in 
the major groove.The hedamycin C8 anglosamine, which 
is absent in the altromycins, positions to the 3’ side of the 
intercalation site to associate with the noncovalently mod- 
ified strand, specifically 7C, the cytosine base-paired to the 
modified guanine. The Cl 0 linked N,N-dimethyl- 
vancosamine present in both altromycin B and hedamycin 
orients to the 5’ side of the modified guanine. Although 
the equivalent Cl 0 sugar in altromycin B also interacts in 
the minor groove to the 5’ side of the intercalation site, the 
interaction of the N,N-dimethylvancosamine moiety with 
DNA differs between the two analogs. The hedamycin 
Cl 0 linked aminosaccharide interacts with the pyrimidine 
3T located on the covalently modified strand. This con- 
trasts with the altromycin B aminodisaccharide, in which 
Fig. 10. Molecular representation of the interaction of the 
hedamycin aminosugars in the minor groove. A water molecule 
mediating the proposed hydrogen bond between the dimethyl- 
amino substituents and the 3T02 and 7CO2 carbonyls is shown 
in white. 
Hedamycin-DNA adduct Hansen et al. 237 
Fig. 11. A proposed evolutionary 
pathway beginning with the anthracy- 
clines and ending with the most potent 
compounds from each pluramycin sub- 
family. The compounds identified as 
possible intermediates in the evolution 
pathway were screened for and iso- 
lated based on activity and may not 
fully represent the complete set of 
compounds in nature. 
the C3” linked neutral altrose moiety interacts with the 
covalently modified strand, while the N,N-dimethylvan- 
cosamine interacts primarily with the non-modified strand 
121. A pyrimidine located to the 5’ side of the modified 
guanine, 5’CG* and 5’TG*, creates a preferred hedamycin 
alkylation sequence, probably through the interaction of 
the 4” dimethylamino group and the pyrimidine 02 car- 
bonyl. A purine in the 5’ position would require the 4” 
dimethylamino group to form a less optimal hydrogen 
bond to the purine N3 position or to create a sterically 
less favorable hydrogen bond to the carbonyl associated 
with the base-paired pyrimidine on the non-modified 
strand. In the case of altromycin B, the reverse situation 
arises in which the dimethylamino group selects for a 
pyrimidine located on the non-modified strand, giving 
rise to the altromycin-preferred sequence 5’AG* 12,131. 
The site of attachment of hedamycin to the DNA mole- 
cule also differs from that of other pluramycins studied. 
While alkylation occurs in a similar fashion through N7 
of guanine in all three compounds studied thus far, the 
hedamycin mechanism of covalent modification occurs 
through Cl 8 of the terminal epoxide rather than Cl6 of 
the proximal epoxide. Attachment to N7 of guanine 
through Cl 8 of hedamycin then creates a four-carbon 
link between the tetracyclic chromophore and the mod- 
ified guanine, as opposed to a two-carbon link in the 
case of altromycin B and sapurimycin. The bonding 
geometry of guanine reacted with a C2 single epoxide 
analog (altromycin U) constrains the modified guanine 
to tilt in the major groove toward the intercalating chro- 
mophore [2,13].This induced strain is alleviated by the 
attachment of hedamycin to DNA through a longer. 
more flexible double epoxide linker. This probably is 
responsible for the modest gain in both alkylation reac- 
tivity and adduct stability demonstrated by hedamycin 
over altromycin B. 
Evolutionary considerations 
It is striking that agents have not been discovered that 
display a combination of glycosidic substitutions drawn 
from both of the pluramycin subfamilies. Specifically, a 
compound that bears an aminosaccharide at the CX posi- 
tion and also has a C5 or C3” altrose substitution has not 
been reported. The reason for this restricted pattern of 
glycosidic substitution is probably due to the steric limi- 
tations imposed by the DNA helix, which would 
decrease the ability of the ligand to covalently modify 
DNA. A hypothetical compound having the Cl 0 amino- 
disaccharide and a C8 aminosugar would not have room 
in the minor groove to accommodate both of these sub- 
stituents. Similarly, an analog possessing a major-groove 
binding C5 substituent and a minor-groove binding CX 
sugar substitution would not easily span the DNA 
double helix from groove to groove. On the basis of 
these observations, the evolutionary scheme shown in 
Figure 11 is proposed for the biosynthesis of the 
pluramycin class of antibiotics. 
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Fig. 12. Chemical structure of the anti-leukemic xanthone 
psorospermin [36]. Structural analogies to the pluramycin chro- 
mophore can be drawn to gain insight into mode of action of 
these agents. 
In light of the structural incompatibilities between sub- 
families, the earliest pluramycin antibiotic probably 
evolved from the anthraquinones, creating a compound 
very similar to sapurimycin. It is then likely that the 
antibiotic-producing organism added an N,N- 
dimethylvancosamine, common to both families, to the 
Cl0 position to yield a compound similar to akino- 
mycin, which would probably react equally well with 
sequences preferred by the classical pluramycins and the 
altromycins. Divergence occurred at this point, creating 
two independent families of compounds. The 
altromycins would be created by adding neutral altroses 
to the C3” and C5 positions, and the classical plura- 
mycins would be created by attaching an anglosamine 
sugar moiety to the C8 position. Consequently, the 
most structurally advanced and biologically potent 
analogs of each subfamily, altromycin B and hedamycin, 
have independently evolved from a common ancestor 
to form the most DNA-reactive compounds of the 
pluramycin family, each preferentially recognizing 
mutually exclusive DNA sequence targets. 
Comparison of pluramycins to psorospermin 
By comparing chemical structure, one can draw several 
parallels to the anti-leukemic agent psorospermin (Fig. 
12) [33]. The psorospermin structure has a 
dihydrofuranoxanthone skeleton with an attached 
epoxide that appears to function similarly to that of the 
pluramycins [34] .The xanthone moiety could intercalate 
into the DNA molecule, placing the 3,4 benzofuran 
into the major groove. The epoxide attached through 
C2 of the benzofuran could then easily alkylate N7 of 
guanine located in the major groove in a similar fashion 
to the pluramycins. Due to the R stereochemistry at the 
C2’ position, however, alkylation would be restricted to 
a guanine residue located to the 5’ side of the DNA 
intercalation site as opposed to the 3’ side, as in the case 
of the pluramycins. In vivo studies using psorospermin 
show that the cytotoxicity of this agent correlates well 
with the formation of abasic sites and abasic-dependent 
lesions such as protein-DNA cross-links and DNA 
strand breaks. This would suggest that the biologically 
significant DNA lesion would not necessarily be the 
drug-DNA adduct but the abasic site resulting from 
drug-induced depurination of the guanine residue. 
Given the information from this study, design efforts 
may need to focus on agents that form less stable 
adducts that readily depurinate. It may also be important 
to consider the possible role that alkylation to the 5’ side 
of intercalation plays in achieving depurination. 
Significance 
The structure of the DNA-hedamycin complex 
determined in these studies, together with the 
known structure of the DNAaltromycin complex, 
has yielded an understanding of the carbohydrate- 
mediated sequence-dependent alkylation displayed 
by the pluramycin family of DNA interactive 
agents. Only a few clearly documented examples 
of carbohydrate-mediated DNA interaction have 
been described to date. The pluramycins embody 
three modes of interaction with DNA. First, they 
have an anthraquinone ring system that inter- 
calates into the DNA. Second, they have an 
attached aminosugar that binds in the minor 
groove upon DNA complexation. Third, in con- 
junction with the basic anthraquinone structure, 
the pluramycins have evolved a 1,2 pyran ring 
system upon which they have attached multiple 
possible epoxide functionalities that can covalently 
modify DNA through N7 of guanine. In this 
respect, the pluramycin-DNA lesion is closely 
analogous to that created by the highly mutagenic 
DNA intercalator-alkylator aflatoxin [35]. 
To be effective against tumors in vivo, the 
designed agents should maximize tumor cell- 
specific cytotoxicity. Selective uptake of a cyto- 
toxic agent at the cellular level would appear to 
be crucial unless unique intracellular targets can 
be identified within cancer cells. At the intra- 
cellular level, selectivity can be achieved either at 
the level of DNA sequence or through inter- 
action with pharmacologically selective receptors 
on or associated with DNA [36]. If ligand- 
induced mutagenicity and antitumor activity is a 
function of DNA sequence selectivity, then mod- 
ification of the glycosidic substitutions at the 
various corners of the pluramycin chromophore 
should be able to modulate these biological 
properties. 
Materials and methods 
Sample preparations 
The self-complementary d(GATGTACATC) DNA strand was 
synthesized on an automated DNA synthesizer (Applied 
Biosystems 381A) using the solid phase phosphoramidite 
method. The DNA synthesis was performed on a lo-pmol 
scale, leaving the final dimethoxytrityl group on the 5’ end of 
the DNA molecules. The crude sample was deprotected in 
concentrated NH,OH at 55 “C overnight and purified by 
reverse phase chromatography on a Cl8 column (Dynamax- 
300A). Purified DNA was then detritylated by dissolving in 
80 o/o acetic acid for 30 min, followed by ether extraction to 
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remove the acetic acid. The Fample was then extensively dia- 
lyzed and buffer was adjusted to 10 mM NaH,PO,, 100 mM 
NaCl. 0.5 mM EDTA, pH 6.8. 
Hcdamycin samples were a gift from the Drug Synthesis and 
Chemistry Branch, l>evelopmental Therapeutics Program, 
I>ivision of Cancer Treatment, National Cancer Institute, and 
were used without further purification. Drug-DNA adduct 
formation was achieved by adding a 2:l molar ratio of 
hedamycin to the purified DNA sample and mixing at 5 -C 
for several hours. Adduct formation was monitored by one- 
dimensional NMR until complete alkylation of the DNA had 
occurred. After addition of drug, the pH was checked and 
readjusted to pH 6.8. 1)ue to aggregation problems, samples 
were diluted to 1 .O-2.0 mM adduct concentrations and 
expcriment~ were performed at 30 ‘C. In bet\\.een experi- 
ments, samples were stored inside NMR tubes at -70 -C to 
minimize decomposition due to depurination of the 
hed‘lmycin-guatiine adduct. 
NMR experiments 
All NMR experiments were performed on a Bruker AMX 
.500 spectrometer in 99.96 ‘% D,O or 95 o/o H10:5 ‘% D20. 
Phase-sensitive. tppi two-dime&ional NOESY, TOCSY and 
[>QF-COSY experiments [27-301 were performed on 
samples dissolved in D,O. For these experiments, 1 K data 
points were acquired in tl \vith a spectral width of 5000 Hz. 
To observe exchangeable protons, a two-dimensional NOESY 
spectrum was obtained with 150 ms mixing delay in H,O 
using a 1-I echo pulse sequence [37-391 to suppress the water 
reconance. In thic experiment, 1 K of data points were 
obtained in tl \vith a sweep width of 12 000 Hz. Select 
carbon-l 3 resonances were identified and characterized using 
HMQC atid HMBC experiments in D20 [40,41]. 
Due to a limited sample life, interproton distance constraints 
were calculated from a single 150 ms NOESY spectrum in 
D,O, obtained with 32 scans per increment, 6000 Hz sweep 
width, and a 5 s relaxation delay between scans. Data was multi- 
plied by a 7r/2 shifted sinebell squared window function, zero 
filled to 2 K and Fourier transformed using Felix 2.0 NMK 
data processing software. Interproton cross-peak’; were inte- 
grated and sorted by volume into sixteen distinct bins: four each 
for proton-proton cross-peaks, methyl-proton cross-peaks, 
dimethylamino-proton cross-peaks and methyl-dimethylamino 
cross-peaks, corresponding to very Ftrong, strong, medium and 
weak connectivitiep. Upper and lower constraint boundaries 
were created using the coordinate averages for the protons in 
the methyl and dimethylaminos.The respective boundaries for 
each group are: 2.2-3.5, 2.6-4.0, 3.0-4.5, 3.5-5.5; 2.2-3.5, 
2.6-1.0, 3.0-5.0, 3.5-6.0; 2.2-4.0, 2.1-3.5, 3.0-6.5, 4,s7.0; 
and 4.0-5.0, 3.0-5.5, 5.0-7.0, 3.5-8.0. 
Modeling 
The SANDER (Simulated Annealing with NMR Driven 
Energy Restraints) module of AMBER 4.0 [42] was used to 
perform energy refinement with these NM&derived 
distance constraints to derive a model of the 
hedamycin-d(GATG*TACATC)Z diadduct.The AMBER force 
field was used with the addition of pseudo energy terms consist- 
ing of a flat well potential with parabolic boundaries for each 
inter-proton connectivity measured. Hedamycin partial atomic 
charges, calculated by MOPAC 5.0, were incorporated into the 
force field parameters for electrostatic energy calculations. 
Additionally, bond, torsion and angle parameters calculated for 
carbohydrate? [43] were included for enerw calculations con- 
cerning the 5accharide moieties in the drug molccule.The N7 of 
the modified guanine was parameterized assuming planar. 
cp2 hybridization. 
Initial DNA structures were created with the NUCGEN 
module of AMBER and adjusted in MILlAS (-131 to form 
intercalation sites and to dock the hedamycin nlolecule. The 
hedamycin structure was generated by minimizing the 
reported X-ray structure [20] The starting structure was then 
solvated with approxmiately 600 water molecules, subjected to 
30 pi of belly dynamics holding the drug-l>NA adduct rigid, 
minimized, and then slowly heated to 300 K over IO ps. In the 
initial period of molecular dynamlcc, interproton distance coil- 
straints were slowly incorporated to 10 kcal mol--’ A--‘. The 
system was then maintained at 300 K for 90 ps and minimized 
ifI 1jocfI0. without constraints, to obtain the reported structure. 
Supplementary material available 
Included ac supplemental material is a list of constraint? and 
final constraint violations. 
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